Neurocrine Biosciences (NBIX) Capital Expenditures Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -21.54% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 881.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -86.92% |
| Dec 31, 2025 | -106.42% |
| Sep 30, 2025 | 1,480.00% |
| Jun 30, 2025 | -11.39% |
| Mar 31, 2025 | -4.46% |
| Dec 31, 2024 | 2,237.50% |
| Sep 30, 2024 | -2,600.00% |
| Jun 30, 2024 | -4,050.00% |
| Mar 31, 2024 | 1,766.67% |
| Dec 31, 2023 | 111.43% |
| Sep 30, 2023 | -99.28% |
| Jun 30, 2023 | 110.53% |
| Mar 31, 2023 | -78.57% |
| Dec 31, 2022 | -257.30% |
| Sep 30, 2022 | 12.20% |
| Jun 30, 2022 | -190.48% |
| Mar 31, 2022 | 2,700.00% |
| Dec 31, 2021 | -9.18% |
| Sep 30, 2021 | 6,050.00% |
| Jun 30, 2021 | 2,000.00% |